LifeVantage Corporation announced a study on Protandim which was presented at the 2014 Experimental Biology Conference held April 26-30, 2014 in San Diego, California.
Experimental Biology is an annual meeting attended by more than 14,000 scientists. The theme for 2014 was “Transforming the Future through Science.” The Colorado State University study entitled Oxidative Stress is Decreased with Short-Term Protandim Use. The placebo-controlled double-blind study supplemented overweight/obese adults with ages from 45-69 for 30-days with LifeVantage’s Protandim international formula currently sold in Japan. The results indicated a significant reduction in markers of oxidative stress in subjects receiving this Protandim formulation.
Dr. Shawn Talbott, LifeVantage Chief Science Officer of LifeVantage commented, “We are pleased to see clinical studies involving our unique products. This research will be added to our large and growing portfolio of scientific studies and builds on the growing collection of evidence supporting Nrf2 activation and oxidative stress reduction associated with Protandim. In addition, this study demonstrates that both of our formulations of Protandim are potent oxidative stress reducers. This allows us to offer people a powerful Nrf2 activator and oxidative stress reduction product in most jurisdictions.”
Abstracts of the conference can be found at the Journal of the Federation of American Societies for Experimental Biology.
Rebecca Scalzo, Janelle Davis, Joseph Beals, Laurie Biela, Gregory Giordano, Hunter Paris Benjamin Miller, Karyn Hamilton, and Christopher Bell, (2014) Oxidative stress is decreased with short-term Protandim use when piperine is substituted for ashwagandha (LB399) FASEB J April 28:LB399.
Other Protandim studies can be viewed at Protandim Pubmed Studies